321 related articles for article (PubMed ID: 14747633)
1. Impact of pain on depression treatment response in primary care.
Bair MJ; Robinson RL; Eckert GJ; Stang PE; Croghan TW; Kroenke K
Psychosom Med; 2004; 66(1):17-22. PubMed ID: 14747633
[TBL] [Abstract][Full Text] [Related]
2. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
4. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
5. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
6. The outcome of physical symptoms with treatment of depression.
Greco T; Eckert G; Kroenke K
J Gen Intern Med; 2004 Aug; 19(8):813-8. PubMed ID: 15242465
[TBL] [Abstract][Full Text] [Related]
7. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
8. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
Polsky D; Onesirosan P; Bauer MS; Glick HA
J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
[TBL] [Abstract][Full Text] [Related]
9. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
[TBL] [Abstract][Full Text] [Related]
10. Are paroxetine, fluoxetine, and sertraline equally effective for depression?
Straton JB; Cronholm P
J Fam Pract; 2002 Mar; 51(3):285. PubMed ID: 11978244
[No Abstract] [Full Text] [Related]
11. Newer generation antidepressants for depressive disorders in children and adolescents.
Hetrick SE; McKenzie JE; Cox GR; Simmons MB; Merry SN
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD004851. PubMed ID: 23152227
[TBL] [Abstract][Full Text] [Related]
12. [Selective serotonin reuptake inhibitors--current knowledge].
Dudek D; Zieba A; Siwek M; Wróbel A
Psychiatr Pol; 2004; 38(3):507-24. PubMed ID: 15199659
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on sertraline in the management of major depressive disorder in elderly patients.
Muijsers RB; Plosker GL; Noble S
CNS Drugs; 2002; 16(11):789-94. PubMed ID: 12383038
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.
Zhang Y; Becker T; Ma Y; Koesters M
BMC Psychiatry; 2014 Aug; 14():245. PubMed ID: 25159460
[TBL] [Abstract][Full Text] [Related]
15. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
[TBL] [Abstract][Full Text] [Related]
16. Depression and comorbid panic in primary care patients.
DeVeaugh-Geiss AM; West SL; Miller WC; Sleath B; Kroenke K; Gaynes BN
J Affect Disord; 2010 Jun; 123(1-3):283-90. PubMed ID: 19828203
[TBL] [Abstract][Full Text] [Related]
17. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
Hong J; Novick D; Montgomery W; Moneta MV; Dueñas H; Peng X; Haro JM
Asia Pac Psychiatry; 2016 Mar; 8(1):51-9. PubMed ID: 25808275
[TBL] [Abstract][Full Text] [Related]
19. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Finley PR
Ann Pharmacother; 1994 Dec; 28(12):1359-69. PubMed ID: 7696728
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
